ReleaseWire Connect

According to the latest Biotech-Report for Germany conducted by Boston Consulting Group for VFA Bio, Germany remains the second largest manufacturer of active biopharmaceutical substances licenced by the European Union, with biopharmaceutical sales accounting for 30.8% of the overall medicines market. Based on the current study, biopharmaceutical sales (in the pharma and hospital sector) reached €14.6 billion in 2020, up 14% from the previous year.

Over the last century pharmaceutical researchers have been able to produce increasingly effective medications based on particular active components. Thanks to professionals in the research and development roles, we as a global society have been able to overcome numerous epidemics in very short periods of time through innovative and ground-breaking treatments.

The development of more effective drug treatments to help those infected with COVID-19 is underway across Germany. Medicines of varying types, such as antiviral medicines, cardiovascular medicines, dampening immunomodulators, and medicines for lung function are being developed to help those suffering from the virus. According to the American organisation BIO, more than 600 different drugs are now being investigated to determine whether they can aid in combatting COVID-19 in any way. Most have previously been authorised or are in the process of being authorised for another illness. Repurposing drugs tends to be a faster way to yield development, rather than researching medications from scratch.

Opportunities for research, innovation, and corporate expansion must all be considered within a biotechnological strategy for growth. Public-private corporations have the potential to foster such growth with the establishment of centres of excellence. Prospects include technologies that integrate components of pharmaceutical research and molecular biology which will drive the industry forward. Discovering and supplying medications that comply with the biology and pathophysiology of each unique patient will be one of the most pressing challenges facing the biotechnology sector in the 21st century. The move from mass-produced medicine to bespoke medicine will have a significant impact on the future development and prescribing of medications.

Clinical studies are crucial to progress in life sciences and new figures have revealed that Germany is one of the top locations in the world for clinical jobs. Research from Germany Trade and Invest has found that there were more than 2,000 clinical studies in Germany in 2020. The country is now one of the top 5 locations in the world for clinical studies and continues to push the envelope where innovation and progress is concerned. Major indication areas include cardiovascular and infectious diseases, as well as oncology, diabetes and inflammatory diseases.

R&D spend has been a priority in Germany over the past decade, making this one of the prime locations in Europe for R&D jobs. The most recent government data has revealed that spending on R&D in Germany is gradually getting closer to an initially ambitious target that was set - 3.5% of GDP. The data comes from the Federal Report for Research and Innovation and shows that Germany has made significant progress towards this R&D spending target. In fact, according to the figures spending has gone above 3% of GDP, which is an impressive achievement.

While there is no doubt that COVID-19 has had a significant impact on many areas of life sciences, drawing funds and resources to its cause, there are still R&D projects that continue to thrive. Cell and gene therapy is one of these areas because, despite the fact that the effects of the pandemic were far-reaching, the number of advanced therapy medicinal product (ATMP) clinical trials continued to increase throughout 2020.

Clinical careers across the spectrum have been influenced by the advance of COVID-19 over the past year - and in many different ways. Research ethics is one area that has faced a number of key challenges since March 2020, as the fight against the virus at the heart of the pandemic has forced progress at high speed. Research Ethics Committees (RECs) have been at the forefront of tackling many of these challenges and analysis has revealed the ways in which RECs have coped with these difficulties on a practical level.

Germany has one of the largest pharmaceutical production industries in the world. They have well-trained professionals, state-of-the-art technical facilities and, close proximity to other industries throughout Europe. Germany's particular strengths lie in the complex production of biopharmaceuticals and as the European leader, in terms of the number of active ingredients produced, staggeringly as a country Germany sit in second place just after the United States when it comes to worldwide positionings. If you're looking to take your career to the next level, the German biopharmaceutical industry is a great place to explore rewarding opportunities that can guarantee both career-progression and personal growth.

Germany represents one of the European states that have halted the rollout of the COVID-19 AstraZeneca vaccine following 37 reports of blood clots, out of more than 17 million people vaccinated in the European Union and United Kingdom. After the EU's European Medicines Agency's meeting, they stated that "It's [the vaccine's] benefits in protecting people from Covid-19 with the associated risks of death and hospitalisation [that] outweigh the possible risks." This review swiftly prompted EU States such as Germany, France and Spain to resume their vaccine rollout. Pharmacovigilance professionals play an important role in the medical industry and protect public health by ensuring drug safety through the collection, detection, assessment, monitoring, and prevention of the adverse effects of pharmaceutical products.